Anti-ADAR2

Anti-ADAR2
Item number Size Datasheet Manual SDS Delivery time Quantity Price
ELK-ES1600.50 50 µl - -

10 - 14 business days*

169.00€
ELK-ES1600.100 100 µl - -

10 - 14 business days*

283.00€
 
This gene encodes the enzyme responsible for pre-mRNA editing of the glutamate receptor subunit B... more
Product information "Anti-ADAR2"
This gene encodes the enzyme responsible for pre-mRNA editing of the glutamate receptor subunit B by site-specific deamination of adenosines. Studies in rat found that this enzyme acted on its own pre-mRNA molecules to convert an AA dinucleotide to an AI dinucleotide which resulted in a new splice site. Alternative splicing of this gene results in several transcript variants, some of which have been characterized by the presence or absence of an ALU cassette insert and a short or long C-terminal region. [provided by RefSeq, Jul 2008], Protein function: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2 and GRIK2) and serotonin (HTR2C), GABA receptor (GABRA3) and potassium voltage-gated channel (KCNA1). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alter their functional activities. Edits GRIA2 at both the Q/R and R/G sites efficiently but converts the adenosine in hotspot1 much less efficiently. Can exert a proviral effect towards human immunodeficiency virus type 1 (HIV-1) and enhances its replication via both an editing-dependent and editing-independent mechanism. The former involves editing of adenosines in the 5'UTR while the latter occurs via suppression of EIF2AK2/PKR activation and function. Can inhibit cell proliferation and migration and can stimulate exocytosis. [The UniProt Consortium] Recommended dilutions: Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/20000. Not yet tested in other applications.. Cellular localization: Nucleus . Nucleus, nucleolus . Shuttles between nucleoli and the nucleoplasm. ., [Isoform 1]: Nucleus . Nucleus, nucleolus ., [Isoform 2]: Nucleus . Nucleus, nucleolus .
Keywords: Anti-RNA-editing enzyme 1, Anti-RNA-editing deaminase 1, Anti-dsRNA adenosine deaminase, Anti-Double-stranded RNA-specific editase 1, ADAR2 rabbit pAb
Supplier: ELK Biotechnology
Supplier-Nr: ES1600

Properties

Application: WB, IHC, IF, ELISA
Antibody Type: Polyclonal
Conjugate: No
Host: Rabbit
Species reactivity: human, mouse, rat
Immunogen: The antiserum was produced against synthesized peptide derived from human ADARB1. AA range:481-530
MW: 80 kD
Format: Antiserum

Handling & Safety

Storage: -20°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Anti-ADAR2"
Write a review
or to review a product.
Viewed